We observed significant increases in the concentration of C3a in the plasma of patients with MS and C5a in the plasma of both healthy controls and patients with MS in response to IA treatment with the miniaturized adsorbers, suggesting complement activation. The gene discussed is C3; the disease is myeloid sarcoma.